Safety and Efficacy Study of Target Therapy Combined With Radiotherapy to Treat Senile Locally Advanced SCCHN

NCT01393184 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

92

Enrollment

OTHER

Sponsor class

Conditions

SCCHN

Interventions

DRUG: Nimotuzumab and Radiotherapy

Sponsor

Peking University

Collaborators

[object Object]